Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

IMNM

Immunome Inc

Sep 06 • 04:00PM ET

13.54

Dollar change -0.68
Percentage change -4.78	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM XBI VXF IWO VTWO VHT IWC LABU ITOT

Index	RUT	P/E	-	EPS (ttm)	-7.69	Insider Own	18.40%	Shs Outstand	60.05M	Perf Week	-11.15%
Market Cap	813.08M	Forward P/E	-	EPS next Y	-2.82	Insider Trans	0.96%	Shs Float	49.00M	Perf Month	8.67%
Income	-262.59M	PEG	-	EPS next Q	-0.54	Inst Own	79.08%	Short Float	25.61%	Perf Quarter	-10.63%
Sales	10.78M	P/S	75.42	EPS this Y	26.26%	Inst Trans	-0.12%	Short Ratio	15.39	Perf Half Y	-50.48%
Book/sh	4.23	P/B	3.20	EPS next Y	28.83%	ROA	-155.54%	Short Interest	12.55M	Perf Year	119.45%
Cash/sh	4.64	P/C	2.92	EPS next 5Y	-	ROE	-199.56%	52W Range	6.13 - 30.96	Perf YTD	26.54%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-48.48%	ROI	-102.45%	52W High	-56.26%	Beta	1.80
Dividend TTM	-	Quick Ratio	7.12	Sales past 5Y	0.00%	Gross Margin	87.40%	52W Low	120.88%	ATR (14)	1.01
Dividend Ex-Date	-	Current Ratio	7.12	EPS Y/Y TTM	-249.14%	Oper. Margin	-2518.49%	RSI (14)	44.14	Volatility	8.13% 6.65%
Employees	55	Debt/Eq	0.01	Sales Y/Y TTM	62.73%	Profit Margin	-2435.02%	Recom	1.00	Target Price	30.60
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-32.29%	Payout	-	Rel Volume	0.77	Prev Close	14.22
Sales Surprise	26.64%	EPS Surprise	-58.14%	Sales Q/Q	-44.55%	Earnings	Aug 12 AMC	Avg Volume	815.43K	Price	13.54
SMA20	-5.76%	SMA50	-2.50%	SMA200	-13.19%	Trades		Volume	628,246	Change	-4.78%

Date	Action	Analyst	Rating Change	Price Target Change
May-31-24	Initiated	Piper Sandler	Overweight	$27
Apr-30-24	Initiated	JP Morgan	Overweight	$24
Apr-15-24	Initiated	Guggenheim	Buy	$35
Jan-29-24	Initiated	Leerink Partners	Outperform	$30
Dec-19-23	Initiated	Wedbush	Outperform	$12
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight	$35

Aug-29-24 08:00AM	Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-20-24 03:26PM	Immunome Stock Sees RS Rating Jump To 91 (Investor's Business Daily) +6.36%
Aug-12-24 05:15PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +7.04%
04:01PM	Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-25-24 08:00AM	Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities (Business Wire) +5.67%
07:30AM	Loading…
07:30AM	Nectin Therapeutics Licenses Novel Antibodies to Immunome (PR Newswire)
Jul-09-24 07:00AM	STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors (GlobeNewswire)
Jun-27-24 08:00AM	Immunome Appoints Phil Tsai as Chief Technical Officer (Business Wire)
May-22-24 02:05PM	Hedge Fund and Insider Trading News: David Tepper, Stanley Druckenmiller, Oaktree Capital Management, Odey Asset Management, ProFrac Holding Corp. (ACDC), Immunome Inc (IMNM), and More (Insider Monkey) +5.64%
May-21-24 07:01PM	Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares (GuruFocus.com)
May-20-24 11:14AM	Immunome Completes Purchase of Antibodies From Atreca (MT Newswires)
08:00AM	Immunome Announces Completion of Purchase of Assets from Atreca (Business Wire)
May-17-24 08:51AM	Immunome Appoints Max Rosett as CFO (MT Newswires)
08:00AM	Immunome Announces Promotion of Max Rosett to Chief Financial Officer (Business Wire)
May-14-24 01:54PM	IMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -5.70%
09:10AM	Loading…
09:10AM	Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Immunome Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-08-24 08:00AM	Immunome to Present at 2024 Bank of America Healthcare Conference (Business Wire)
May-02-24 08:00AM	Immunome Appoints Kinney Horn as Chief Business Officer (Business Wire)
Apr-30-24 07:29AM	--JPMorgan Starts Immunome With Overweight Rating, $24 Price Target (MT Newswires)
Apr-26-24 10:00AM	Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-25-24 08:26AM	Immunome Appoints Sandra M. Swain to Board of Directors (Business Wire)
Apr-05-24 08:00AM	Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting (Business Wire)
Mar-28-24 11:53PM	IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.41%
04:02PM	Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets (Business Wire)
Mar-26-24 08:00AM	Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala (Business Wire) +5.79%
08:00AM	Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome (GlobeNewswire)
Mar-18-24 05:44AM	Arrayjets ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies (Business Wire)
Mar-07-24 08:00AM	Immunome to Participate in the Leerink Partners Global Biopharma Conference (Business Wire)
Mar-04-24 07:00AM	Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors (GlobeNewswire)
08:00AM	Loading…
Mar-01-24 08:00AM	Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference (Business Wire) +5.17%
Feb-20-24 08:15AM	Immunome Recognizes Ayala Pharmaceuticals Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors (Business Wire) -10.99%
08:00AM	Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors (GlobeNewswire)
Feb-16-24 04:05PM	Immunome Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire) +14.74%
Feb-13-24 10:38PM	Immunome Announces Pricing of Public Offering of Common Stock (Business Wire)
04:05PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
Feb-07-24 08:34AM	Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up (Zacks) +7.83%
Feb-06-24 09:20AM	Immunome pays $50M for phase 3 desmoid tumor drug, playing catch-up with SpringWorks (FierceBiotech.com) +36.91%
08:00AM	Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals (Business Wire)
Feb-05-24 08:00AM	Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (Business Wire)
Jan-08-24 07:00AM	Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform (Business Wire) +7.91%
Jan-04-24 08:00AM	Immunome Appoints Phil Roberts as Chief Technical Officer (Business Wire)
Jan-03-24 08:00AM	Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +7.27%
Jan-02-24 08:00AM	Immunome Appoints Carol A. Schafer to Board of Directors (Business Wire)
Dec-26-23 08:30AM	Immunome to Acquire Antibody-Related Assets and Materials from Atreca (Business Wire) +8.20%
08:30AM	Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome (GlobeNewswire)
Nov-10-23 08:00AM	Immunome to Present at the Stifel 2023 Healthcare Conference (Business Wire) -5.49%
Nov-09-23 08:00AM	Immunome Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-08-23 08:00AM	Immunome Appoints Jean-Jacques Bienaim to Board of Directors (Business Wire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-19-23 08:00AM	Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer (Business Wire)
Oct-04-23 11:00PM	Insider Buying: Immunome Inc's President and CEO Clay Siegall Acquires 169,204 Shares (GuruFocus.com)
Oct-03-23 08:00AM	Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies (Business Wire)
Aug-17-23 08:19PM	Inside the deal: How Immunome and MophImmune came to a merger agreement (American City Business Journals)
Aug-09-23 08:00AM	Immunome Reports Second Quarter 2023 Financial Results (Business Wire)
Jun-30-23 09:51AM	Immunome (IMNM) Surges on Merger Agreement With Morphimmune (Zacks)
Jun-29-23 09:00AM	Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies (PR Newswire) +30.29%
Jun-02-23 07:55AM	Immunome's (NASDAQ:IMNM) investors will be pleased with their favorable 45% return over the last year (Simply Wall St.)
May-23-23 04:05PM	Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity (Business Wire) +11.57%
May-09-23 08:50AM	Here's What Could Help Immunome, Inc. (IMNM) Maintain Its Recent Price Strength (Zacks) +8.51%
May-05-23 08:00AM	Immunome Reports First Quarter 2023 Financial Results (Business Wire)
Apr-20-23 08:50AM	Immunome, Inc. (IMNM) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Mar-16-23 08:00AM	Immunome Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire) +9.24%
Mar-13-23 07:32AM	Immunome, Inc.'s (NASDAQ:IMNM) Shift From Loss To Profit (Simply Wall St.)
Mar-09-23 08:45AM	Immunome to Present at 13th Annual World ADC London Conference (Business Wire)
Feb-08-23 08:00AM	Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board (Business Wire)
Jan-31-23 06:52AM	Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-06-23 04:05PM	AbbVie Briefly Breaks Out After Tapping Immunome In $30 Million Cancer Deal (Investor's Business Daily) -15.47%
02:46PM	Immunome enters into a cancer drug collaboration with AbbVie worth up to $2.8B (American City Business Journals)
10:35AM	Immunome Stock Jumps On Discovery Pact With AbbVie (Benzinga)
08:00AM	AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets (PR Newswire)
Nov-14-22 08:00AM	Immunome Reports Third Quarter 2022 Financial Results (Business Wire)
Nov-09-22 12:00PM	Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (Business Wire)
Oct-04-22 06:08AM	Immunome, Inc.'s (NASDAQ:IMNM) Shift From Loss To Profit (Simply Wall St.)
Aug-24-22 06:59AM	Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation (Simply Wall St.)
Aug-23-22 09:00AM	Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer (Business Wire) +5.96%
Aug-05-22 08:00AM	Immunome Reports Second Quarter 2022 Financial Results (Business Wire) +17.41%
Jul-06-22 09:28AM	Immunome's COVID-19 Cocktail Retains Neutralizing Activity Against Omicron Subvariants (Benzinga) +12.57%
08:00AM	Immunomes COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1 (Business Wire)
Jun-09-22 08:00AM	Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19 (Business Wire)
Jun-02-22 08:00AM	Immunome to Present at the Jefferies Healthcare Conference (Business Wire)
May-26-22 08:07AM	Immunome, Inc. (NASDAQ:IMNM) insider upped their holding by earlier this year (Simply Wall St.) +8.33%
May-23-22 08:00AM	Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38 (Business Wire)
May-19-22 03:27PM	Immunome Shares Rise After Publishing Positive COVID-19 Antibody Cocktail Data (Benzinga) +17.96%
11:31AM	Immunome shares soar on positive testing data for its experimental Covid therapy (American City Business Journals)
08:00AM	Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant (Business Wire)
May-12-22 08:00AM	Immunome Reports First Quarter 2022 Financial Results (Business Wire) +10.43%
Mar-28-22 08:00AM	Immunome Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire) +23.03%
Mar-17-22 06:40AM	Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth (Simply Wall St.) +7.73%
Mar-14-22 12:30PM	Immunome (IMNM) COVID-19 Cocktail Hold Lifted, Shares Gain (Zacks)
Mar-11-22 10:48AM	FDA Lifts Clinical Hold on Immunome's COVID-19 Candidate IND (Benzinga) -7.96%
08:00AM	FDA Lifts Clinical Hold on Immunomes IMM-BCP-01 IND Application for the Treatment of COVID-19 (Business Wire)
Feb-08-22 03:00PM	Immunome Shares Seesaw After COVID-19 Antibody Cocktail Works Against Live Omicron Virus (Benzinga)
10:22AM	Immunome shares seesaw after reporting antibody 'cocktail' passes test against live omicron virus (American City Business Journals)
08:00AM	Immunomes Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing (Business Wire)
Jan-11-22 09:56AM	Immunome stock sinks after testing of its experimental Covid-19 'cocktail' delayed by FDA (American City Business Journals)
06:46AM	FDA Issues Clinical Hold On Immunome's COVID-19 Antibody Program (Benzinga)
Jan-10-22 04:15PM	Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19 (Business Wire)
Dec-17-21 07:11AM	Bullish Immunome, Inc. (NASDAQ:IMNM) insiders filled their treasuries with US$628k worth of stock over last year (Simply Wall St.)
Dec-07-21 07:00AM	Immunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald (Business Wire)

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIENAIME JEAN JACQUES	Director	Aug 16 '24	Buy	13.94	7,000	97,608	16,615	Aug 19 09:07 PM
Higgins Jack	Chief Scientific Officer	Aug 15 '24	Option Exercise	1.35	19,524	26,357	19,524	Aug 19 09:05 PM
Higgins Jack	Chief Scientific Officer	Aug 15 '24	Sale	13.93	3,524	49,072	16,000	Aug 19 09:05 PM
Higgins Jack	Officer	Aug 15 '24	Proposed Sale	13.93	3,524	49,073		Aug 15 03:21 PM
BIENAIME JEAN JACQUES	Director	May 21 '24	Buy	13.57	2,000	27,140	9,615	May 22 04:49 PM
SIEGALL CLAY B	President and CEO	May 20 '24	Buy	13.91	79,566	1,106,524	399,202	May 21 04:13 PM
SIEGALL CLAY B	President and CEO	May 21 '24	Buy	13.78	20,434	281,548	419,636	May 21 04:13 PM
SIEGALL CLAY B	President and CEO	Oct 02 '23	Buy	5.91	169,204	999,996	319,636	Oct 04 05:35 PM
Turner Bruce	Chief Strategy Officer	Oct 02 '23	Buy	5.91	42,300	249,993	42,300	Oct 04 05:32 PM

Open in Screener

BMRN

Biomarin Pharmaceutical Inc.

Sep 06 • 04:00PM ET

84.08

Dollar change -1.04
Percentage change -1.22	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

BMRN Biomarin Pharmaceutical Inc. daily Stock Chart

Held by: IJH VTI VO VXF XBI VUG MDY IBB VOT USMV

Index	-	P/E	63.48	EPS (ttm)	1.32	Insider Own	1.26%	Shs Outstand	188.60M	Perf Week	-7.98%
Market Cap	16.01B	Forward P/E	27.02	EPS next Y	3.11	Insider Trans	-7.75%	Shs Float	187.98M	Perf Month	-2.57%
Income	256.59M	PEG	1.48	EPS next Q	0.53	Inst Own	98.51%	Short Float	3.54%	Perf Quarter	4.00%
Sales	2.59B	P/S	6.18	EPS this Y	130.96%	Inst Trans	2.05%	Short Ratio	2.95	Perf Half Y	-2.11%
Book/sh	27.77	P/B	3.03	EPS next Y	54.86%	ROA	3.76%	Short Interest	6.65M	Perf Year	-7.60%
Cash/sh	6.43	P/C	13.07	EPS next 5Y	43.00%	ROE	5.10%	52W Range	73.68 - 99.56	Perf YTD	-12.80%
Dividend Est.	-	P/FCF	69.36	EPS past 5Y	-	ROI	4.36%	52W High	-15.55%	Beta	0.33
Dividend TTM	-	Quick Ratio	1.95	Sales past 5Y	10.23%	Gross Margin	77.79%	52W Low	14.12%	ATR (14)	2.45
Dividend Ex-Date	-	Current Ratio	3.05	EPS Y/Y TTM	154.18%	Oper. Margin	10.02%	RSI (14)	36.70	Volatility	3.72% 2.53%
Employees	3401	Debt/Eq	0.21	Sales Y/Y TTM	18.10%	Profit Margin	9.91%	Recom	1.61	Target Price	112.52
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	87.65%	Payout	0.00%	Rel Volume	0.70	Prev Close	85.12
Sales Surprise	7.24%	EPS Surprise	53.72%	Sales Q/Q	19.18%	Earnings	Aug 05 AMC	Avg Volume	2.26M	Price	84.08
SMA20	-6.78%	SMA50	-2.71%	SMA200	-3.81%	Trades		Volume	1,580,812	Change	-1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-24	Upgrade	Bernstein	Mkt Perform → Outperform	$94 → $110
May-17-24	Downgrade	Robert W. Baird	Outperform → Neutral	$104 → $72
May-14-24	Initiated	Evercore ISI	Outperform	$113
Nov-15-23	Initiated	Wells Fargo	Overweight	$100
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform	$82
Sep-28-23	Initiated	Raymond James	Mkt Perform
Sep-18-23	Initiated	UBS	Buy	$120
Jul-27-23	Initiated	Scotiabank	Sector Perform	$95
Jul-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$102
Jun-14-23	Resumed	Credit Suisse	Outperform	$120
Mar-21-23	Initiated	Bernstein	Underperform	$81
Feb-22-23	Downgrade	Oppenheimer	Outperform → Perform
Feb-21-23	Initiated	Citigroup	Neutral	$116
Jan-30-23	Initiated	BMO Capital Markets	Market Perform	$107
Jan-18-23	Initiated	Canaccord Genuity	Hold	$119
Oct-31-22	Upgrade	Oppenheimer	Perform → Outperform	$92 → $110
Jul-13-22	Initiated	Cantor Fitzgerald	Overweight	$110
Jun-13-22	Resumed	Wedbush	Neutral	$146 → $70
Apr-25-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$96 → $113
Nov-22-21	Upgrade	William Blair	Mkt Perform → Outperform

Show Previous Ratings

Sep-04-24 01:30PM	BioMarin, having retrenched, outlines plans for growth (BioPharma Dive)
01:00PM	BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance (PR Newswire)
11:30AM	Why Is BioMarin (BMRN) Up 5.4% Since Last Earnings Report? (Zacks)
07:30AM	BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time (PR Newswire)
Aug-29-24 11:53AM	BioMarin lays off 225 employees in restructuring efforts (Pharmaceutical Technology)
09:50AM	Loading…
09:50AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock (Zacks)
08:15AM	BioMarin to lay off over 200 employees (BioPharma Dive)
08:00AM	BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY (PR Newswire)
04:12AM	The most expensive drugs in the US (Pharmaceutical Technology)
Aug-28-24 12:45PM	Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
Aug-23-24 07:56AM	Is the Options Market Predicting a Spike in BioMarin (BMRN) Stock? (Zacks)
Aug-21-24 08:30AM	BioMarin Announces New R&D and Business Development Leadership (PR Newswire)
07:00AM	BioMarin taps Amgen, Roche vets in executive reshuffle (BioPharma Dive)
Aug-19-24 09:00AM	BioMarin to Host 2024 Investor Day on September 4th in New York (PR Newswire)
10:34AM	Loading…
Aug-13-24 10:34AM	Here's Why You Should Invest in BioMarin (BMRN) Stock Now (Zacks)
09:50AM	Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-12-24 12:45PM	BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Aug-09-24 09:15AM	BioMarin Pharmaceutical Inc (BMRN): Are Hedge Funds Bullish on This Elliott Management-Approved Stock Now? (Insider Monkey)
Aug-06-24 02:42PM	When Product Launches Struggle, Biotech Investors Reward Cost Cuts (The Wall Street Journal) +7.95%
01:35PM	Q2 2024 Biomarin Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
11:51AM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
10:35AM	BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View (Zacks)
07:45AM	BioMarin pares Roctavian spending as it narrows sales focus (BioPharma Dive)
Aug-05-24 06:00PM	BioMarin (BMRN) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates (Zacks)
04:15PM	BioMarin: Q2 Earnings Snapshot (Associated Press Finance)
04:03PM	BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance (PR Newswire)
04:01PM	BioMarin Announces Updated Strategy for ROCTAVIAN to Focus on U.S., Germany and Italy (PR Newswire)
Jul-31-24 09:15AM	Wall Street's Insights Into Key Metrics Ahead of BioMarin (BMRN) Q2 Earnings (Zacks)
06:33AM	Loading…
Jul-25-24 06:33AM	FDA agrees wider use of BioMarins BRINEURA for CLN2 (Pharmaceutical Technology)
Jul-24-24 04:05PM	U.S. Food and Drug Administration Approves BioMarin's BRINEURA (cerliponase alfa) for Children Under 3 Years with CLN2 Disease (PR Newswire)
12:10PM	Why BioMarin (BMRN) is Poised to Beat Earnings Estimates Again (Zacks)
Jul-23-24 08:00AM	BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET (PR Newswire)
Jul-22-24 10:01AM	BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q2 Release (Zacks)
Jul-15-24 08:41AM	Is The Options Market Predicting A Spike In BioMarin Pharmaceutical (BMRN) Stock? (Zacks)
Jul-01-24 09:20AM	Here's Why Parnassus Value Equity Fund Sold BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Jun-20-24 03:18AM	Should You Hold BioMarin Pharmaceutical (BMRN) Despite Setback? (Insider Monkey)
Jun-17-24 08:30AM	BioMarin to Present Data Highlighting Significant Impact of VOXZOGO (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health (PR Newswire)
Jun-11-24 10:57AM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
Jun-07-24 06:09PM	KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
09:00AM	BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress (PR Newswire)
Jun-05-24 06:14AM	June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge (InvestorPlace)
Jun-04-24 08:00AM	BridgeBio data show sustained benefit for achondroplasia drug (BioPharma Dive)
May-25-24 11:10PM	20 Biggest Publicly Traded Biotech Companies (Insider Monkey)
May-24-24 11:31AM	BioMarin (BMRN) Down 7.6% Since Last Earnings Report: Can It Rebound? (Zacks)
May-18-24 05:06AM	4 Incomparable Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market (Motley Fool)
May-15-24 07:00AM	Novo Holdings buys stake in life sciences tools company; BioMarin lays off 170 (BioPharma Dive)
May-13-24 04:14PM	Biomarin Pharmaceutical Insider Sold Shares Worth $3,255,200, According to a Recent SEC Filing (MT Newswires)
May-09-24 06:15AM	The 3 Best Biotech Stocks to Buy in May 2024 (InvestorPlace)
May-08-24 08:00AM	BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV (PR Newswire)
May-06-24 07:00PM	Insider Sale: EVP, Chief Commercial Officer Jeffrey Ajer Sells 5,000 Shares of Biomarin ... (GuruFocus.com)
04:47PM	Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing (MT Newswires)
May-04-24 04:00PM	New Data for BioMarin's VOXZOGO (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting (PR Newswire)
May-03-24 02:31PM	Citi Just Cut Its Price Target on These 3 Stocks (InvestorPlace)
Apr-29-24 02:26PM	BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says (MT Newswires)
Apr-27-24 05:06AM	4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market (Motley Fool)
01:07AM	Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN) (GuruFocus.com)
Apr-26-24 08:49AM	BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:53AM	Pfizer hemophilia gene therapy arrives in US to uncertain future (BioPharma Dive)
Apr-25-24 01:30PM	CureVac N.V. (NASDAQ:CVAC) Q4 2023 Earnings Call Transcript (Insider Monkey) -9.90%
11:48AM	BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales (Zacks)
11:44AM	Scotiabank Adjusts Price Target on BioMarin Pharmaceutical to $85 From $83, Maintains Sector Perform Rating (MT Newswires)
10:47AM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
10:31AM	Wells Fargo Adjusts Price Target on BioMarin Pharmaceutical to $110 From $100, Maintains Overweight Rating (MT Newswires)
07:39AM	BioMarin drops drug programs in pipeline cull (BioPharma Dive)
06:46AM	Q1 2024 Biomarin Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
03:19AM	Biomarin Pharmaceutical Inc (BMRN) Q1 2024 Earnings Call Transcript Highlights: Strong Growth ... (GuruFocus.com)
Apr-24-24 06:30PM	BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:33PM	BioMarin Pharmaceutical Inc. (BMRN) Q1 2024 Earnings: Surpasses Revenue and EPS Estimates (GuruFocus.com)
05:15PM	BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates (Zacks)
04:23PM	BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Increase -- Shares Down After Hours (MT Newswires)
04:14PM	BioMarin: Q1 Earnings Snapshot (Associated Press Finance)
04:03PM	BioMarin Reports Record Financial Results for the First Quarter 2024 (PR Newswire)
Apr-23-24 11:36AM	Is a Surprise Coming for BioMarin (BMRN) This Earnings Season? (Zacks)
Apr-22-24 04:26PM	BioMarin Pharmaceutical Investors to Focus Q1 on Strategic Review, Cost-Cutting Measures, UBS Says (MT Newswires)
09:16AM	Gear Up for BioMarin (BMRN) Q1 Earnings: Wall Street Estimates for Key Metrics (Zacks)
Apr-17-24 10:01AM	BioMarin Pharmaceutical (BMRN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-12-24 07:00PM	Insider Sell: Biomarin Pharmaceutical Inc (BMRN) Chief Accounting Officer Erin Burkhart ... (GuruFocus.com)
Apr-10-24 08:00AM	BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET (PR Newswire)
Apr-01-24 07:01PM	Insider Sell: EVP, Chief Legal Officer George Davis Sells 24,602 Shares of Biomarin ... (GuruFocus.com)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-16-24 05:06AM	4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market (Motley Fool)
Mar-12-24 08:30AM	New Data to be Presented for BioMarin's VOXZOGO (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting (PR Newswire)
Mar-11-24 10:00AM	BioMarin Pharmaceutical: Pioneering Innovations Are Driving Future Growth (GuruFocus.com)
Mar-08-24 01:31AM	Insider Sell: President, Worldwide R&D Henry Fuchs Sells 35,341 Shares of Biomarin ... (GuruFocus.com)
Mar-07-24 08:30AM	BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer (PR Newswire)
Mar-01-24 09:00AM	BioMarin Scheduled to Participate in March Investor Conferences (PR Newswire)
Feb-27-24 12:03AM	Decoding Biomarin Pharmaceutical Inc (BMRN): A Strategic SWOT Insight (GuruFocus.com)
Feb-26-24 02:36PM	REFILE-UPDATE 2-BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies (Reuters)
02:12PM	REFILE-BioMarin Pharma gets DOJ subpoena on certain drug testing programs (Reuters)
Feb-23-24 04:29PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
12:33PM	BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2023 Earnings Call Transcript (Insider Monkey)
11:34AM	BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales (Zacks)
07:21AM	Q4 2023 Biomarin Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
05:43AM	20 Fastest Growing Biotech Companies in the US (Insider Monkey)
04:25AM	BioMarin preaches patience amid slow sales for hemophilia gene therapy (BioPharma Dive)
Feb-22-24 06:00PM	Here's What Key Metrics Tell Us About BioMarin (BMRN) Q4 Earnings (Zacks)
05:15PM	BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates (Zacks)
04:42PM	BioMarin Pharmaceutical Inc. (BMRN) Announces Record Financial Results for 2023 (GuruFocus.com)

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burkhart Erin	GVP, Chief Accounting Officer	Aug 13 '24	Sale	90.00	714	64,260	14,449	Aug 15 03:57 PM
Burkhart Erin	Officer	Aug 13 '24	Proposed Sale	90.00	714	64,260		Aug 13 11:48 AM
HERON ELAINE J	Director	Jun 03 '24	Option Exercise	63.10	5,047	318,466	101,888	Jun 04 07:29 PM
MEIER RICHARD A	Director	Jun 03 '24	Option Exercise	63.10	6,600	416,460	126,227	Jun 04 07:28 PM
Mueller Brian	EVP, Chief Financial Officer	May 30 '24	Option Exercise	63.10	5,000	315,500	77,159	May 31 06:28 PM
Mueller Brian	EVP, Chief Financial Officer	May 30 '24	Sale	75.19	5,000	375,950	72,159	May 31 06:28 PM
Davis George Eric	EVP, Chief Legal Officer	May 28 '24	Option Exercise	63.10	40,850	2,577,635	97,007	May 30 06:18 PM
Davis George Eric	EVP, Chief Legal Officer	May 28 '24	Sale	74.51	40,850	3,043,802	56,157	May 30 06:18 PM
BIENAIME JEAN JACQUES	Director	May 09 '24	Option Exercise	63.10	20,000	1,262,000	494,994	May 13 03:57 PM
BIENAIME JEAN JACQUES	Director	May 10 '24	Option Exercise	63.10	20,000	1,262,000	494,994	May 13 03:57 PM
BIENAIME JEAN JACQUES	Director	May 09 '24	Sale	81.62	20,000	1,632,400	474,994	May 13 03:57 PM
BIENAIME JEAN JACQUES	Director	May 10 '24	Sale	81.14	20,000	1,622,800	474,994	May 13 03:57 PM
Davis George Eric	EVP, Chief Legal Officer	May 02 '24	Option Exercise	63.10	1,850	116,735	58,007	May 06 04:45 PM
Davis George Eric	EVP, Chief Legal Officer	May 02 '24	Sale	85.01	1,850	157,268	56,157	May 06 04:45 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	May 02 '24	Sale	82.91	5,000	414,550	66,767	May 06 04:40 PM
BIENAIME JEAN JACQUES	Director	Apr 11 '24	Option Exercise	63.10	20,000	1,262,000	494,994	Apr 15 04:21 PM
BIENAIME JEAN JACQUES	Director	Apr 12 '24	Option Exercise	63.10	20,000	1,262,000	494,994	Apr 15 04:21 PM
BIENAIME JEAN JACQUES	Director	Apr 12 '24	Sale	91.26	20,000	1,825,200	474,994	Apr 15 04:21 PM
BIENAIME JEAN JACQUES	Director	Apr 11 '24	Sale	90.99	20,000	1,819,800	474,994	Apr 15 04:21 PM
Burkhart Erin	GVP, Chief Accounting Officer	Apr 10 '24	Sale	90.00	2,286	205,740	16,156	Apr 12 03:07 PM
Davis George Eric	EVP, Chief Legal Officer	Mar 28 '24	Sale	88.34	24,602	2,173,341	55,856	Apr 01 04:54 PM
Slamon Dennis	Director	Mar 18 '24	Option Exercise	79.70	10,000	797,000	40,809	Mar 20 05:13 PM
FUCHS HENRY J	President, Worldwide R&D	Mar 05 '24	Sale	85.18	35,341	3,010,396	212,117	Mar 07 06:54 PM
BIENAIME JEAN JACQUES	Director	Mar 06 '24	Sale	86.71	1,000	86,713	560,203	Mar 07 05:35 PM
BIENAIME JEAN JACQUES	Director	Mar 05 '24	Sale	85.51	1,000	85,510	561,203	Mar 07 05:35 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Mar 05 '24	Sale	87.07	4,000	348,280	94,047	Mar 07 05:32 PM
BIENAIME JEAN JACQUES	Director	Feb 27 '24	Sale	90.35	1,000	90,350	562,203	Feb 29 05:05 PM
BIENAIME JEAN JACQUES	Director	Feb 08 '24	Option Exercise	63.10	15,000	946,500	434,602	Feb 12 05:20 PM
BIENAIME JEAN JACQUES	Director	Feb 09 '24	Option Exercise	63.10	15,000	946,500	434,602	Feb 12 05:20 PM
BIENAIME JEAN JACQUES	Director	Feb 08 '24	Sale	89.77	15,000	1,346,550	419,602	Feb 12 05:20 PM
BIENAIME JEAN JACQUES	Director	Feb 09 '24	Sale	88.28	15,000	1,324,200	419,602	Feb 12 05:20 PM
BIENAIME JEAN JACQUES	Director	Jan 09 '24	Option Exercise	63.10	10,000	631,000	435,162	Jan 11 02:40 PM
BIENAIME JEAN JACQUES	Director	Jan 10 '24	Option Exercise	63.10	10,000	631,000	435,162	Jan 11 02:40 PM
BIENAIME JEAN JACQUES	Director	Jan 09 '24	Sale	98.19	10,000	981,900	425,162	Jan 11 02:40 PM
BIENAIME JEAN JACQUES	Director	Jan 10 '24	Sale	96.38	10,000	963,800	425,162	Jan 11 02:40 PM
BIENAIME JEAN JACQUES	Director	Dec 21 '23	Option Exercise	63.10	10,000	631,000	435,112	Dec 22 05:14 PM
BIENAIME JEAN JACQUES	Director	Dec 21 '23	Sale	93.99	10,000	939,900	425,112	Dec 22 05:14 PM
Davis George Eric	EVP, Chief Legal Officer	Dec 13 '23	Sale	95.30	13,764	1,311,709	55,710	Dec 14 06:18 PM

IMNM

Immunome Inc

BMRN

Biomarin Pharmaceutical Inc.

Upgrade your FINVIZ experience